PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.00 - 0.01
0.00 - 0.02
289 / 496.9K (Avg.)
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-19.18%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-35.15%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-2.26%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-2.26%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-74.84%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-50.00%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-50.00%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
-21.50%
Share reduction while ECL.AX is at 2.64%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-18.24%
Reduced diluted shares while ECL.AX is at 0.68%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
169.04%
Positive OCF growth while ECL.AX is negative. John Neff would see this as a clear operational advantage vs. the competitor.
159.89%
Positive FCF growth while ECL.AX is negative. John Neff would see a strong competitive edge in net cash generation.
-79.60%
Both companies have negative long-term revenue/share growth. Martin Whitman would question if the entire market or product set is shrinking.
-73.73%
Both face negative 5Y revenue/share CAGR. Martin Whitman would suspect macro headwinds or obsolete product offerings across the niche.
-42.67%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
186.98%
Positive long-term OCF/share growth while ECL.AX is negative. John Neff would see a structural advantage in sustained cash generation.
11.96%
Positive OCF/share growth while ECL.AX is negative. John Neff might see a comparative advantage in operational cash viability.
688.12%
Positive 3Y OCF/share CAGR while ECL.AX is negative. John Neff might see a big short-term edge in operational efficiency.
No Data
No Data available this quarter, please select a different quarter.
113.40%
Below 50% of ECL.AX's 829.19%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
45.44%
Positive short-term CAGR while ECL.AX is negative. John Neff would see a clear advantage in near-term profit trajectory.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.46%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
16.00%
Inventory growth well above ECL.AX's 6.30%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
6.53%
Positive asset growth while ECL.AX is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
99.56%
Positive BV/share change while ECL.AX is negative. John Neff sees a clear edge over a competitor losing equity.
15.85%
Debt growth of 15.85% while ECL.AX is zero. Bruce Berkowitz sees additional leverage that must yield profitable expansions to be worthwhile.
-50.02%
Our R&D shrinks while ECL.AX invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
3.76%
We expand SG&A while ECL.AX cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.